[{"arm_notes": "", "treatment_id": null, "treatment_name": "Intervention1: SNG001: SNG001 will be dosed daily for 14 days as this was the duration of dosing in Phase I and II studies. With this dosing schedule data from the SG016 study in which hospitalized patients with confirmed COVID-19 were randomized to either SNG001 or placebo revealed an increased likelihood to recover to \u00e2??no limitation of symptoms\u00e2?? over the treatment period and at day 28 as defined by a post-baseline WHO OSCI of 0 or 1 (Figure 2.2-3). This effect was most pronounced after 9 days of dosing; with dosing having commenced a mean of 9 days after first developing COVID-19 symptoms. Importantly; in this study the median duration of hospitalization was approximately 7 days; and thus participants continued to self-administer study product at home post discharge; with continued clinical improvement.Intervention2: SAB185: Two doses of SAB-185 will be studied in this study. Each dose is considered separately; as its own agent group.Intervention3: BMS-986414 (C135-LS) and BMS-986413 (C144-LS): BMS-986414 (C135-LS) and BMS-986413 (C144-LS) were identified and cloned at the Rockefeller Universityfrom two individuals who recovered from COVID-19 (8). Participants will be randomized to receive one of the following regimens: Investigational Agent: C135-LS 200 mg and C144-LS 200 mg to be administered subcutaneously (SC) for one dose at study Entry/Day 0.Control Intervention1: Active Comparator: In this study an active comparator will be used instead of a placebo in phase III evaluations for participants who are at higher risk for progression to hospitalization or death. The active comparator is a combination of monoclonal antibodies (casirivimab and imdevimab) made by Regeneron. This combination agent was granted EUA for the treatment of mild to mode", "treatment_type": "TODO", "pharmacological_treatment": "TODO"}]

[{"arm_notes": "", "treatment_id": 1140, "treatment_name": "Sab-185", "treatment_type": "Monoclonal antibodies", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 1210, "treatment_name": "Sng001 nebuliser solution", "treatment_type": "Interferons", "pharmacological_treatment": "Pharmacological treatment"}, {"arm_notes": "", "treatment_id": 2187, "treatment_name": "Placebo", "treatment_type": "Placebo", "pharmacological_treatment": "Placebo"}]